Moran Wealth Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Moran Wealth Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,320	Closed	-$356K	–	431
2023 Q1	$356K	Sell	3,320 -1,972	-37%	-$227K	0.01%	315
2022 Q4	$582K	Buy	+5,292	New	+$343K	0.02%	288

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Moran Wealth Management's RXDX Position: Q2 2023 in Review

Moran Wealth Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,320 shares — an estimated $356K sold.

Moran Wealth Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $582K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Moran Wealth Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Moran Wealth Management sold 3,320 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $356K.
Moran Wealth Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Moran Wealth Management's Prometheus Biosciences, Inc. Common Stock position peaked at $582K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Moran Wealth Management's 13F filing for Q2 2023, filed 10 Aug 2023.